Zavegepant Intranasal

Zavegepant Intranasal is a prescription medication used for the acute treatment of migraine with or without aura. 

• Zavegepant Intranasal is available under the following different brand names: Zavzpret.

Common side effects of Zavegepant Intranasal include:

• Nausea,
• Vomiting, 
• Burning sensation in the nose, 
• Loss of sense of taste, and
• Change in sense of taste.

Serious side effects of Zavegepant Intranasal include:

• Hives, 
• Rash,
• Difficulty breathing, and
• Swelling of the face, lips, tongue, or throat

Rare side effects of Zavegepant Intranasal include:

• None 

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, loss of coordination, feeling unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Intranasal solution

• 10 mg/spray

Migraine

• 10 mg single spray in 1 nostril as needed
• Not to exceed 10 mg/24 hours period
• Safety of treating above 8 migraines/30 days has not been established.

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”

If your medical doctor is using this medicine to treat your pain, your doctor or pharmacist may already be aware of any possible drug interactions and may be monitoring you for them. Do not start, stop, or change the dosage of any medicine before checking with your doctor, health care provider, or pharmacist first.

• Zavegepant Intranasal has severe interactions with no other drugs.
• Zavegepant Intranasal has serious interactions with at least 29 other drugs.
• Zavegepant Intranasal has moderate interactions with no other drugs.
• Zavegepant Intranasal has minor interactions with no other drugs.

This information does not contain all possible interactions or adverse effects. Visit the RxList Drug Interaction Checker for any drug interactions. Therefore, before using this product, tell your doctor or pharmacist about all your products. Keep a list of all your medications with you and share this information with your doctor and pharmacist. Check with your healthcare professional or doctor for additional medical advice, health questions, or concerns.

Contraindications

• History of hypersensitivity to zavegepant or other ingredients

Effects of drug abuse

• None

Short-Term Effects

• See “What Are Side Effects Associated with Using Zavegepant Intranasal?”

Long-Term Effects

• See “What Are Side Effects Associated with Using Zavegepant Intranasal?”

Cautions

• Hypersensitivity reactions reported, including facial swelling and urticaria; initiate appropriate therapy if hypersensitivity occurs
• Ask the patient to discuss prescriptions, OTC medications, or herbal supplements that they take or plan to take.
• Drug interaction overview
  • Substrate of OATP1B3 and NTCP
    • OATP1B3 or NTCP inhibitors
    • Avoid coadministration.
    • Inhibitors of organic anion-transporting polypeptide 1B3 (OATP1B3) or sodium taurocholate transporting polypeptide (NTCP) transporters may significantly increase zavegepant exposure.
  • OATP1B3 or NTCP inducers
    • Avoid coadministration.
    • Inducers of OATP1B3 or NTCP transporters may decrease zavegepant exposure.
  • Intranasal decongestants
• Dosage modification
  • Avoid coadministration; if unavoidable, administer intranasal decongestants at least 1 hour after zavegepant
  • Coadministration may decrease systemic exposure and efficacy of zavegepant.

Pregnancy and Lactation

• Data are not available on the developmental risk associated with the use in pregnant females.
• Clinical considerations
  • Data suggest that women with migraine may be at increased risk for preeclampsia and gestational hypertension during pregnancy.
• Lactation
  • Data regarding the presence of zavegepant or its metabolites in human milk, effects on breastfed infants, or effects on milk production are unavailable.